Cargando…

Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis

BACKGROUND: To evaluate immunotherapy against canine visceral leishmaniasis, Leishmania major antigen and heat-killed Mycobacterium vaccae (SRL172) were used as stimulators of immune defense mechanisms and the results were compared with standard chemotherapy meglumine antimoniate. METHODS: Nineteen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jamshidi, Sh, Avizeh, R, Mohebali, M, Bokaie, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3279897/ https://www.ncbi.nlm.nih.gov/pubmed/22347294

Ejemplares similares

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

Correction: Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

HISTORICAL SERIES OF PATIENTS WITH VISCERAL LEISHMANIASIS TREATED WITH MEGLUMINE ANTIMONIATE IN A HOSPITAL FOR TROPICAL DISEASES, MACEIÓ-AL, BRAZIL
por: Silveira, Lindon Johoson Diniz, et al.
Publicado: (2015)

Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime(®)) and the recombinant Leish-110f(®) + MPL-SE(®) vaccine to treat canine visceral leishmaniasis
por: Miret, Jorge, et al.
Publicado: (2008)

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
por: Yazdanpanah, Mohamad Javad, et al.
Publicado: (2011)

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
por: Vasconcellos, Erica de Camargo Ferreira e, et al.
Publicado: (2014)

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)
por: Gómez, María Adelaida, et al.
Publicado: (2020)

Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia
por: Rojas Cabrera, Ernesto, et al.
Publicado: (2022)

Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran
por: Aflatoonian, Mohammad Reza, et al.
Publicado: (2019)

Therapeutic Effect of Sodium Selenite and Zinc Sulphate as Supplementary with Meglumine Antimoniate( Glucantime®) Against Cutaneous Leishmaniasis In BALB/C Mice
por: Sorkhroodi, F Zamani, et al.
Publicado: (2010)

Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients
por: de Oliveira Bezerra, Débora Cristina, et al.
Publicado: (2017)

The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate
por: Omidian, Mohammad, et al.
Publicado: (2019)

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
por: Valete-Rosalino, Cláudia Maria, et al.
Publicado: (2014)

Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate
por: Perez-Franco, Jairo E., et al.
Publicado: (2016)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
por: Berger, Brandon A., et al.
Publicado: (2017)

Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis
por: Goyonlo, Vahid Mashayekhi, et al.
Publicado: (2019)

Hoigne Syndrome Caused by Intralesional Meglumine Antimoniate
por: Guarneri, Claudio, et al.
Publicado: (2017)

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
por: Layegh, Pouran, et al.
Publicado: (2011)

FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
por: Ribeiro, Madelon Novato, et al.
Publicado: (2014)

Dressings Combined with Injection of Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial
por: Khatami, Alireza, et al.
Publicado: (2013)

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
por: LYRA, Marcelo Rosandiski, et al.
Publicado: (2016)

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis
por: Berenguer, Diana, et al.
Publicado: (2019)

Therapeutic Potential of Green Synthesized Copper Nanoparticles Alone or Combined with Meglumine Antimoniate (Glucantime(®)) in Cutaneous Leishmaniasis
por: Albalawi, Aishah E., et al.
Publicado: (2021)

Tissue distribution of residual antimony in rats treated with multiple doses of meglumine antimoniate
por: Coelho, Deise Riba, et al.
Publicado: (2014)

Effect of hydroalcoholic extract of Echinacea purpurea in combination with meglumine antimoniate on treatment of Leishmania major-induced cutaneous leishmaniasis in BALB/c mice
por: Sarkari, Bahador, et al.
Publicado: (2017)

Modification on Direct Agglutination Antigen Preparation for Simplified Sero-Diagnosis of Human and Canine Visceral Leishmaniasis
por: MOHEBALI, Mehdi, et al.
Publicado: (2015)

A Novel Strategy for Enhance Potentiation of Meglumine antimoniate against Leishmania major In Vitro
por: MIRZAEI, Farzaneh, et al.
Publicado: (2019)

Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
por: da Silva, Rosiana Estéfane, et al.
Publicado: (2016)

Effects of Meglumine Antimoniate Treatment on Cytokine Production in a Patient with Mucosal Leishmaniasis and Chagas Diseases Co-Infection
por: Rezende-Oliveira, Karine, et al.
Publicado: (2020)

American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate
por: Senchyna, A., et al.
Publicado: (2020)

Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis
por: Brito, Nayara C., et al.
Publicado: (2019)

Antileishmanial potentials of azacitidine and along with meglumine antimoniate on Leishmania major: In silico prediction and in vitro analysis
por: Derakhshani, Ali, et al.
Publicado: (2023)

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine
por: Borja-Cabrera, Gulnara Patricia, et al.
Publicado: (2004)

Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study
por: Castro, Maria del Mar, et al.
Publicado: (2017)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016)

Neurological toxicity due to antimonial treatment for refractory visceral leishmaniasis
por: Maristany Bosch, Marta, et al.
Publicado: (2021)

Meglumine Antimoniate and Miltefosine Combined With Allopurinol Sustain Pro-inflammatory Immune Environments During Canine Leishmaniosis Treatment
por: Santos, Marcos Ferreira, et al.
Publicado: (2019)

Neutrophil Activation: Influence of Antimony Tolerant and Susceptible Clinical Strains of L. (V.) panamensis and Meglumine Antimoniate
por: Fernández, Olga Lucía, et al.
Publicado: (2021)

Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
por: Ramalho, Dario Brock, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bcp41cqkol24vu001kleefoqe8